FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular to a fusion protein – IL-6 antagonist. Said fusion protein contains a fragment of the extracellular domain of the IL-6R protein, represented by an amino acid sequence corresponding to positions 20–361 of SEQ ID NO: 1 with the substitution D358A, and the human IgG4 Fc fragment, attached to the IL-6R protein fragment from the C-terminus without a linker or by means of a linker sequence. Present invention also relates to an isolated nucleic acid molecule coding said fusion protein, an expression vector and a cell.
EFFECT: present invention provides a high degree of safety of therapeutic application of said protein and its potentially improved pharmacokinetic properties.
11 cl, 1 dwg, 2 ex
Title | Year | Author | Number |
---|---|---|---|
NUCLEOTIDE SEQUENCE CODING FUSED PROTEIN CONSISTING OF SOLUBLE EXTRACELLULAR FRAGMENT OF HUMAN PDGFRA AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IGG4 | 2023 |
|
RU2821574C1 |
NUCLEOTIDE SEQUENCE CODING FUSED PROTEIN CONSISTING OF FUNCTIONAL FRAGMENT OF HUMAN IL-1RA AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IgG4 | 2023 |
|
RU2821896C1 |
NUCLEOTIDE SEQUENCE ENCODING FUSED PROTEIN CONSISTING OF SOLUBLE EXTRACELLULAR FRAGMENT OF HUMAN Dll4 AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IgG4 | 2021 |
|
RU2787060C1 |
NUCLEOTIDE SEQUENCE, WHICH CODES A FUSION PROTEIN CONSISTING OF A SOLUBLE EXTRACELLULAR DOMAIN OF HUMAN TNFR1 AND A CONSTANT PORTION OF A HEAVY CHAIN OF HUMAN IgG4 | 2018 |
|
RU2689522C1 |
FUSED IMMUNOGLOBULIN PROTEINS | 2008 |
|
RU2530168C2 |
ANTIBODIES OF HIGH AFFINITY TO IL-6-RECEPTOR OF HUMANS | 2007 |
|
RU2433138C2 |
MODIFIED INTERLEUKIN-7 PROTEIN AND METHODS FOR USE THEREOF | 2016 |
|
RU2708160C2 |
IMMUNOCYTOKINE FOR ACTIVATION OF HUMAN IL-10Rα RECEPTOR AND ITS USE | 2020 |
|
RU2810750C2 |
HUMANISED ANTIBODY (H14,18) BASED ON MOUSE ANTIBODY 14,18, CONTACTING GD2, AND ITS FUSION WITH IL-2 | 2003 |
|
RU2366664C2 |
ACTIVIN-ActRIIa-Fc ANTAGONISTS AND USE THEREOF FOR TREATING OR PREVENTING BREAST CANCER | 2008 |
|
RU2473362C2 |
Authors
Dates
2024-05-02—Published
2023-11-29—Filed